Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about KRRO, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| KRRO-110 | Alpha-1 Anti-trypsin Deficiency | Phase 1/2 · NCT06677307 | Terminated |
| KRRO-121 | Urea Cycle Disorders, Inborn | Phase 1/2 · NCT07773246 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
KRRO holds $124.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $15M/quarter from operations, an estimated runway of 25 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 29 · Moderate
We expect that our cash, cash equivalents and marketable securities outstanding as of September 30, 2026 will be sufficient to fund our operating expenses and capital expenditure requirements into the second half of 2028.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KRRO files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Lynx1 Capital Management LP 10% owner |
Insider | 1,624,789 | 11.84% | 2026-10-22 |
| Venrock Healthcare Capital Partners III, | 5%+ holder (13G) | 1,474,162 | 10.74% | 2026-09-30 |
| Mohamad Makhzoumi 10% owner · +242,945 options |
Insider | 1,297,893 | 9.46% | 2026-03-10 |
| Carmen Chang 10% owner · +242,945 options Includes shares also reported by Mohamad Makhzoumi, counted once |
Insider | 1,297,893 | 9.46% | 2026-03-10 |
| Scott D Sandell 10% owner · +242,945 options Includes shares also reported by Mohamad Makhzoumi, counted once |
Insider | 1,297,893 | 9.46% | 2026-03-10 |
| Forest Baskett 10% owner · +242,945 options Includes shares also reported by Mohamad Makhzoumi, counted once |
Insider | 1,297,893 | 9.46% | 2026-03-10 |
| New Enterprise Associates 17, L.P. 10% owner · +242,945 options Includes shares also reported by Mohamad Makhzoumi, counted once |
Insider | 1,297,893 | 9.46% | 2026-03-10 |
| Edward T Mathers 10% owner · +242,945 options Includes shares also reported by Mohamad Makhzoumi, counted once |
Insider | 1,297,893 | 9.46% | 2026-03-10 |
| Rick Yang 10% owner · +242,945 options Includes shares also reported by Mohamad Makhzoumi, counted once |
Insider | 1,297,893 | 9.46% | 2026-03-10 |
| Anthony A. Jr. Florence 10% owner · +242,945 options Includes shares also reported by Mohamad Makhzoumi, counted once |
Insider | 1,297,893 | 9.46% | 2026-03-10 |
| Paul Edward Walker 10% owner · +242,945 options Includes shares also reported by Mohamad Makhzoumi, counted once |
Insider | 1,297,893 | 9.46% | 2026-03-10 |
| Ali Behbahani Director · +257,622 options Includes shares also reported by Mohamad Makhzoumi, counted once |
Insider | 1,297,893 | 9.46% | 2026-03-10 |
Share count 13,725,646 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KRRO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →